Supplemental material
Journal of Market Access & Health Policy
Volume 10, 2022 - Issue 1
Open access
1,625
Views
1
CrossRef citations to date
0
Altmetric
Original Research Article
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
Lin Fana Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USAView further author information
, Yuanyuan Zhangb Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UKCorrespondence[email protected]
View further author information
, View further author information
Peter Maguireb Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UKView further author information
, Dominic Mustona Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USAView further author information
, Matthew Monbergc Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USAView further author information
, Jagadeswara Rao Earlac Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USAView further author information
, Adela Mihaid Global Health Economics and Payer Evidence, AstraZeneca PLC, Cambridge, UKView further author information
& Poonam Gulatie Global Regulatory Affairs, AstraZeneca PLC, Cambridge, UKView further author information
show all
Article: 2078474
|
Received 28 Jan 2022, Accepted 12 May 2022, Published online: 08 Jun 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.